Jefferies reiterates Buy on Gilead stock, sees lower IRA impact

Jefferies reiterated Buy on Gilead with a $196 price target, about 17% above the cited $167.47 share price, and estimated offsets could reduce the company’s roughly $1.5B 2028 Biktarvy pricing headwind to about $1B. CMS’s maximum fair price is approximately $2,600 per pack, 38% below the $4,216 wholesale acquisition cost, effective January 1, 2028. Separately, Gilead’s Q3 2026 EPS of $2.55 and revenue of $8.3B exceeded estimates of $2.17 and $7.79B; base-business sales grew 16% year over year, and analysts raised price targets.

Analysis

The market question is less the headline 2028 price cut than whether Gilead can keep expanding its HIV franchise fast enough to absorb a concentrated, delayed policy drag. If growth from newer products and other franchises persists, the Medicare exposure is more likely to cap the multiple than impair near-term earnings; if growth decelerates, investors may capitalize the 2028 erosion earlier than the cash-flow timing suggests. Jefferies’ offsets are channel-mix assumptions, not assured economics: spillover into Medicaid and 340B could be smaller, and actual net impact depends on realized utilization and rebate mechanics. Treat the estimated mitigation as a scenario, not a booked offset.

Near term, the strongest counterweight is execution: follow-through in HIV and newer-product uptake, not analyst target changes. Over 1–3 months, any evidence that recent growth is concentrated or guidance-dependent could reverse optimism. Over 6–18 months, watch policy implementation details, channel migration, and whether alternative therapies constrain pricing or share. The contrarian risk is that investors treat a distant, partly mitigated headwind as immaterial; the opposite risk is over-discounting a 2028 event while current franchise growth remains durable. No standalone valuation conclusion follows from this item.

Key Decisions for Investors

• No immediate directional trade on the IRA estimate alone. The timing is distant and the proposed offsets are uncertain; avoid treating the analyst’s scenario as verified earnings relief.
• For the next earnings cycle, track HIV product growth, newer-product uptake, and any change in full-year guidance. A slowdown or guidance rollback would weaken the growth cushion and support reducing exposure; sustained execution would argue against overreacting to the 2028 policy headline.
• Add a watch item for company disclosures on Biktarvy channel mix, realized net pricing, and Medicaid/340B spillover. Reassess the thesis if verified offsets fall materially short of the analyst’s assumed range or implementation details broaden the affected economics.
• Keep the 2028 exposure in long-range earnings scenarios rather than applying the full gross price reduction immediately. Falsifiers are policy terms that worsen the realized net impact, evidence of weaker franchise growth, or guidance that fails to absorb the headwind.